Clovis Oncology Stock Price, News & Analysis (NASDAQ:CLVS)

$54.15 -0.43 (-0.79 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$54.15
Today's Range$54.09 - $56.36
52-Week Range$45.42 - $99.45
Volume675,404 shs
Average Volume1.35 million shs
Market Capitalization$2.63 billion
P/E Ratio-6.54
Dividend YieldN/A
Beta1.05

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CLVS
CUSIP18946410
Phone+1-303-6255000

Debt

Debt-to-Equity Ratio0.94%
Current Ratio3.19%
Quick Ratio3.16%

Price-To-Earnings

Trailing P/E Ratio-6.53985507246377
Forward P/E Ratio-7.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$80,000.00
Price / Sales33,173.64
Cash FlowN/A
Price / CashN/A
Book Value($0.08) per share
Price / Book-676.88

Profitability

Trailing EPS($8.28)
Net Income$-349,130,000.00
Net Margins-947.47%
Return on Equity-122.06%
Return on Assets-38.84%

Miscellaneous

Employees278
Outstanding Shares49,010,000

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology Inc (NASDAQ:CLVS) announced its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.18) by $0.06. The biopharmaceutical company earned $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same quarter in the prior year, the firm posted ($1.70) earnings per share. View Clovis Oncology's Earnings History.

When will Clovis Oncology make its next earnings announcement?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Clovis Oncology.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2018?

17 analysts have issued twelve-month price targets for Clovis Oncology's shares. Their predictions range from $50.00 to $125.00. On average, they expect Clovis Oncology's stock price to reach $90.31 in the next twelve months. View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. According to Zacks Investment Research, "The FDA’s accelerated approval to Clovis’ ovarian cancer treatment, Rubraca in December 2016 was a huge boost for the company. Rubraca registered slower-than- expected sales in the third quarter. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on continued approval for the drug. Rubraca is under review in EU for the same indication. Several studies evaluating Rubraca in different types of ovarian cancer patients are ongoing. Clovis is looking for label expansion in second line or later maintenance treatment for advanced ovarian cancer. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have outperformed the industry in the past year. Loss estimates have widened ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/16/2018)
  • 2. JPMorgan Chase & Co. analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today.   There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)
  • 3. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director (Age 54)
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer (Age 54)
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer (Age 63)
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer (Age 49)
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer (Age 50)
  • Brian G. Atwood, Independent Director (Age 64)
  • James C. Blair Ph.D., Independent Director (Age 77)
  • Keith T. Flaherty M.D., Independent Director (Age 46)
  • Ginger L. Graham, Independent Director (Age 62)

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (6.94%), Franklin Resources Inc. (5.38%), Redmile Group LLC (2.69%), Alliancebernstein L.P. (2.05%), HealthCor Management L.P. (1.99%) and Fred Alger Management Inc. (1.31%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Frontier Capital Management Co. LLC, Teachers Advisors LLC, Emerald Advisers Inc. PA, Sectoral Asset Management Inc, Candriam Luxembourg S.C.A., C WorldWide Group Holding A S and Tocqueville Asset Management L.P.. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Redmile Group LLC, Franklin Resources Inc., Millennium Management LLC, UBS Asset Management Americas Inc., Element Capital Management LLC, Palo Alto Investors LLC and California Public Employees Retirement System. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $54.15.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $2.63 billion and generates $80,000.00 in revenue each year. The biopharmaceutical company earns $-349,130,000.00 in net income (profit) each year or ($8.28) on an earnings per share basis. Clovis Oncology employs 278 workers across the globe.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 Flatiron Pkwy Unit 100, BOULDER, CO 80301-2834, United States. The biopharmaceutical company can be reached via phone at +1-303-6255000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (CLVS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  662
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clovis Oncology (NASDAQ:CLVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.652.652.612.59
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $90.31$90.31$85.47$79.53
Price Target Upside: 64.41% upside64.41% upside30.50% upside13.83% upside

Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History

Price Target History for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Credit Suisse GroupSet Price TargetBuy$107.00 -> $86.00MediumView Rating Details
1/11/2018JPMorgan Chase & Co.Reiterated RatingBuyHighView Rating Details
12/20/2017OppenheimerReiterated RatingHoldHighView Rating Details
11/15/2017Leerink SwannReiterated RatingOutperform$107.00 -> $90.00N/AView Rating Details
11/3/2017Stifel NicolausReiterated RatingBuy$125.00N/AView Rating Details
11/2/2017Morgan StanleyLower Price TargetOverweight$89.00 -> $86.00N/AView Rating Details
10/23/2017BarclaysInitiated CoverageOverweight -> Overweight$105.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$81.00LowView Rating Details
9/11/2017CannReiterated RatingHoldLowView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$73.00HighView Rating Details
8/3/2017Bank of AmericaReiterated RatingBuyLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/22/2017SunTrust BanksReiterated RatingBuyLowView Rating Details
6/20/2017Goldman Sachs GroupReiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Clovis Oncology (NASDAQ:CLVS) Earnings History and Estimates Chart

Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ CLVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($1.29)N/AView Earnings Details
11/1/2017Q3 2017($1.18)($1.24)$21.12 million$16.81 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.27)($1.29)$13.07 million$14.62 millionViewListenView Earnings Details
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
2/28/2013Q4 2012($0.76)($0.81)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.68)($0.71)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.61)($0.61)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.81)($0.74)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.79)($1.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Clovis Oncology (NASDAQ:CLVS) Earnings Estimates

2018 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.38)($1.16)($1.27)
Q2 20182($1.01)($0.68)($0.85)
Q3 20182($0.64)($0.46)($0.55)
Q4 20182($0.17)($0.08)($0.13)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Clovis Oncology (NASDAQ CLVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.50%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ CLVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Gillian C Ivers-ReadInsiderSell3,000$54.09$162,270.00180,571View SEC Filing  
1/16/2018Gillian C Ivers-ReadInsiderSell3,000$59.16$177,480.00183,571View SEC Filing  
1/8/2018Thorlef SpickschenDirectorSell4,500$64.97$292,365.0021,118View SEC Filing  
12/15/2017Gillian C Ivers-ReadInsiderSell3,000$64.16$192,480.00182,583View SEC Filing  
12/8/2017Thorlef SpickschenDirectorSell4,500$60.00$270,000.0025,618View SEC Filing  
11/15/2017Gillian C Ivers-ReadInsiderSell3,000$63.70$191,100.00View SEC Filing  
10/16/2017Gillian C Ivers-ReadInsiderSell3,000$84.54$253,620.00View SEC Filing  
9/15/2017Gillian C Ivers-ReadInsiderSell3,000$69.50$208,500.00191,583View SEC Filing  
8/15/2017Gillian C Ivers-ReadInsiderSell3,000$70.05$210,150.00194,583View SEC Filing  
8/4/2017James C BlairDirectorSell18,450$78.61$1,450,354.502,185View SEC Filing  
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00197,583View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00200,583View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00203,583View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00206,583View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00209,583View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00135,583View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00212,583View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00138,583View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00215,583View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00141,583View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00168,583View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.0034,427View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Clovis Oncology (NASDAQ CLVS) News Headlines

Source:
DateHeadline
Clovis Oncology Inc (CLVS) Receives Consensus Rating of "Hold" from AnalystsClovis Oncology Inc (CLVS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 17 at 10:32 AM
Clovis Oncology Inc (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 SharesClovis Oncology Inc (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares
www.americanbankingnews.com - February 16 at 10:02 PM
Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26
finance.yahoo.com - February 13 at 9:03 AM
Clovis Oncology (CLVS) Scheduled to Post Quarterly Earnings on TuesdayClovis Oncology (CLVS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:38 AM
Clovis Oncology (CLVS) Downgraded by BidaskClubClovis Oncology (CLVS) Downgraded by BidaskClub
www.americanbankingnews.com - February 11 at 8:54 AM
Deciphera Pharmaceuticals (DCPH) and Clovis Oncology (CLVS) Head-To-Head AnalysisDeciphera Pharmaceuticals (DCPH) and Clovis Oncology (CLVS) Head-To-Head Analysis
www.americanbankingnews.com - February 6 at 3:18 PM
$19.22 Million in Sales Expected for Clovis Oncology Inc (CLVS) This Quarter$19.22 Million in Sales Expected for Clovis Oncology Inc (CLVS) This Quarter
www.americanbankingnews.com - February 5 at 5:46 AM
Clovis Oncology Inc (CLVS) Expected to Announce Earnings of -$1.28 Per ShareClovis Oncology Inc (CLVS) Expected to Announce Earnings of -$1.28 Per Share
www.americanbankingnews.com - February 3 at 2:32 PM
Q3 2018 EPS Estimates for Clovis Oncology Inc Raised by SunTrust Banks (CLVS)Q3 2018 EPS Estimates for Clovis Oncology Inc Raised by SunTrust Banks (CLVS)
www.americanbankingnews.com - January 29 at 5:08 AM
Clovis Oncology (CLVS) Raised to Sell at BidaskClubClovis Oncology (CLVS) Raised to Sell at BidaskClub
www.americanbankingnews.com - January 27 at 11:02 AM
Clovis Oncology Inc (CLVS) Expected to Post FY2022 Earnings of $10.84 Per ShareClovis Oncology Inc (CLVS) Expected to Post FY2022 Earnings of $10.84 Per Share
www.americanbankingnews.com - January 26 at 3:16 PM
Clovis Oncology, Inc. (CLVS) Given Consensus Rating of "Hold" by AnalystsClovis Oncology, Inc. (CLVS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 23 at 11:16 AM
AstraZenecas PARP Inhibitor Lynparza Gets Approval in JapanAstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
finance.yahoo.com - January 22 at 3:49 PM
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in JapanAstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
finance.yahoo.com - January 22 at 3:49 PM
Clovis Oncology (CLVS) Given a $86.00 Price Target at Credit Suisse GroupClovis Oncology (CLVS) Given a $86.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - January 21 at 6:56 PM
BidaskClub Lowers Clovis Oncology (CLVS) to Strong SellBidaskClub Lowers Clovis Oncology (CLVS) to Strong Sell
www.americanbankingnews.com - January 21 at 4:24 PM
$19.22 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter$19.22 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter
www.americanbankingnews.com - January 19 at 8:56 AM
Clovis Oncology, Inc. (CLVS) Insider Sells $177,480.00 in StockClovis Oncology, Inc. (CLVS) Insider Sells $177,480.00 in Stock
www.americanbankingnews.com - January 17 at 7:06 PM
Clovis Oncology (CLVS) Rating Lowered to Sell at Zacks Investment ResearchClovis Oncology (CLVS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 16 at 12:44 PM
Today’s Research Reports on Trending Tickers: Clovis Oncology and Incyte CorporationToday’s Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation
finance.yahoo.com - January 12 at 9:49 AM
Clovis Oncology (CLVS) Given "Buy" Rating at JPMorgan Chase & Co.Clovis Oncology (CLVS) Given "Buy" Rating at JPMorgan Chase & Co.
www.americanbankingnews.com - January 11 at 8:22 AM
Insider Selling: Clovis Oncology, Inc. (CLVS) Director Sells 4,500 Shares of StockInsider Selling: Clovis Oncology, Inc. (CLVS) Director Sells 4,500 Shares of Stock
www.americanbankingnews.com - January 9 at 6:52 PM
Clovis Oncology, Inc. (CLVS) to Post Q1 2018 Earnings of ($1.27) Per Share, Leerink Swann ForecastsClovis Oncology, Inc. (CLVS) to Post Q1 2018 Earnings of ($1.27) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 8 at 5:34 AM
Clovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $19.22 MillionClovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $19.22 Million
www.americanbankingnews.com - January 2 at 3:04 AM
Clovis Oncology (CLVS) Raised to Hold at ValuEngineClovis Oncology (CLVS) Raised to Hold at ValuEngine
www.americanbankingnews.com - December 29 at 5:48 PM
Clovis Oncology, Inc. (CLVS) Receives Consensus Recommendation of "Buy" from BrokeragesClovis Oncology, Inc. (CLVS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 29 at 10:28 AM
Clovis Up More Than 50% in 2017: Whats Driving the Stock?Clovis Up More Than 50% in 2017: What's Driving the Stock?
www.zacks.com - December 28 at 3:45 PM
Clovis Oncology (CLVS) Stock Rating Reaffirmed by OppenheimerClovis Oncology (CLVS) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - December 20 at 5:14 PM
Clovis Oncology (CLVS) Announces Rucaparib MAA for Ovarian Cancer Treatment Indication Referred by CHMP to ... - StreetInsider.comClovis Oncology (CLVS) Announces Rucaparib MAA for Ovarian Cancer Treatment Indication Referred by CHMP to ... - StreetInsider.com
www.streetinsider.com - December 19 at 9:48 AM
Insider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of StockInsider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - December 18 at 6:20 PM
 Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million
www.americanbankingnews.com - December 16 at 6:32 AM
Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key ThresholdClovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold
finance.yahoo.com - December 15 at 5:40 PM
 Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.27 Per Share Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.27 Per Share
www.americanbankingnews.com - December 14 at 11:02 PM
Noteworthy Wednesday Option Activity: FNSR, CLVS, UAANoteworthy Wednesday Option Activity: FNSR, CLVS, UAA
www.nasdaq.com - December 13 at 5:16 PM
Value Biotech ETFs to Buy NowValue Biotech ETFs to Buy Now
finance.yahoo.com - December 13 at 5:16 PM
Clovis Oncology (CLVS) Lifted to "Sell" at BidaskClubClovis Oncology (CLVS) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - December 9 at 9:50 AM
Clovis Oncology, Inc. (CLVS) Director Sells $270,000.00 in StockClovis Oncology, Inc. (CLVS) Director Sells $270,000.00 in Stock
www.americanbankingnews.com - December 8 at 11:16 PM
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drugClovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
finance.yahoo.com - December 6 at 9:55 AM
Clovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech MoversClovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech Movers
finance.yahoo.com - December 6 at 9:55 AM
ValuEngine Lowers Clovis Oncology (CLVS) to SellValuEngine Lowers Clovis Oncology (CLVS) to Sell
www.americanbankingnews.com - December 5 at 10:50 PM
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug ApplicationClovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
finance.yahoo.com - December 5 at 5:03 PM
Clovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from AnalystsClovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 4 at 9:41 AM
Commit To Purchase Clovis Oncology At $40, Earn 14.2% Using OptionsCommit To Purchase Clovis Oncology At $40, Earn 14.2% Using Options
www.nasdaq.com - November 28 at 5:06 PM
 Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million
www.americanbankingnews.com - November 28 at 3:50 AM
Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Announce -$1.27 EPSZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Announce -$1.27 EPS
www.americanbankingnews.com - November 26 at 7:32 PM
Clovis Oncology Stock Pullback Offers Opportunity With Strong Q3 NumbersClovis Oncology Stock Pullback Offers Opportunity With Strong Q3 Numbers
seekingalpha.com - November 24 at 3:56 PM
3 Companies Competing to Gain Lead in Ovarian Cancer Market3 Companies Competing to Gain Lead in Ovarian Cancer Market
www.zacks.com - November 24 at 11:09 AM
Today’s Research Reports on Trending Tickers: Ekso Bionics and Clovis OncologyToday’s Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology
finance.yahoo.com - November 20 at 6:23 PM
Leerink Swann Reiterates "Outperform" Rating for Clovis Oncology, Inc. (CLVS)Leerink Swann Reiterates "Outperform" Rating for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - November 19 at 6:20 PM
Leerink Swann Comments on Clovis Oncology, Inc.s FY2018 Earnings (CLVS)Leerink Swann Comments on Clovis Oncology, Inc.'s FY2018 Earnings (CLVS)
www.americanbankingnews.com - November 18 at 9:38 AM

SEC Filings

Clovis Oncology (NASDAQ:CLVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clovis Oncology (NASDAQ:CLVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clovis Oncology (NASDAQ CLVS) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.